PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer

John R. Prensner1,2,14, Wei Chen3,14, Matthew K. Iyer1, Qi Cao1,2, Teng Ma4, Sumin Han3, Anirban Sahu1, Rohit Malik1, Kari Wilder-Romans3, Nora Navone5, Christopher J. Logothetis5, John C. Araujo5, Louis L. Pisters5, Ashutosh K. Tewari6, Christine E. Canman7, Karen E. Knudsen8, Naoki Kitabayashi9, Mark A. Rubin9, Francesca Demichelis9,10, Theodore S. Lawrence7, Arul M. Chinnaiyan1,2,11,12,13,15 and Felix Y. Feng1,3,12,15

1Michigan Center for Translational Pathology, 2Department of Pathology, 3Department of Radiation Oncology, 4Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA 48109
5Department of Genitourinary Medical Oncology, M.D. Anderson Cancer Center, Houston, TX, USA 77030
6Department of Urology, Institute of Prostate Cancer and LeFrak Center For Robotic Surgery, Weill Cornell Medical College and New York Presbyterian Hospitals, New York, New York, USA 10065
7Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA 48109
8Departments of Cancer Biology, Urology, and Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania USA 19107
9Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA 10065
10Centre for Integrative Biology, University of Trento, Trento, Italy 38122
11Department of Urology, 12Comprehensive Cancer Center, and 13Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, Michigan, USA 48109
14These authors contributed equally
15These authors share senior authorship

Running title: PCAT-1 impairs homologous recombination
Key words: prostate cancer, long noncoding RNA, homologous recombination

Address correspondence to:
Felix Y Feng, M.D.
Department of Radiation Oncology
University of Michigan Medical Center
1500 E Medical Center Drive, UHB2C490-SPC5010
Ann Arbor, MI 48109-5010
Phone: 734-936-4302; Fax: 734-763-7371
Email: ffeng@med.umich.edu

Arul M. Chinnaiyan, M.D. Ph.D.
Comprehensive Cancer Center
University of Michigan Medical School
1400 E. Medical Center Dr.
5316 CCGC 5940
Ann Arbor, MI 48109-5940
Phone: 734-615-4062; Fax: 734-615-4055
Email: arul@med.umich.edu
Conflicts of Interest

The University of Michigan has filed a patent on PCAT1 in which A.M.C., J.R.P. and M.K.I. are named as co-inventors. Wafergen, Inc. has a non-exclusive license for creating commercial research assays for the detection of IncRNAs including PCAT1. A.M.C. serves on the Scientific Advisory Board of Wafergen. Wafergen had no role in the design or experimentation of this study, nor has it participated in the writing of the manuscript. A.K.T. is a co-inventor on a patent regarding a prostatectomy method for diagnosing and staging prostate cancer. A.K.T. also has received sponsored funding and/or honoraria from Intuitive Surgical, Boston Scientific, and Medtronics, none of whom were involved in the writing of this manuscript.
ABSTRACT

Impairment of double-stranded DNA break (DSB) repair is essential to many cancers. However, while mutations in DSB repair proteins are common in hereditary cancers, mechanisms of impaired DSB repair in sporadic cancers remain incompletely understood. Here, we describe the first role for a long noncoding RNA (lncRNA) in DSB repair in prostate cancer. We identify PCAT-1, a prostate cancer outlier lncRNA, which regulates cell response to genotoxic stress. PCAT-1 expression produces a functional deficiency in homologous recombination (HR) through its repression of the BRCA2 tumor suppressor, which, in turn, imparts a high sensitivity to small molecule inhibitors of PARP1. These effects reflected a post-transcriptional repression of the BRCA2 3’UTR by PCAT-1. Our observations thus offer a novel mechanism of “BRCA-ness” in sporadic cancers.
INTRODUCTION

The uncontrolled accumulation of double-stranded DNA breaks (DSBs) represents a putative Achilles heel for cancer cells, since these lesions are toxic and their repair requires re-ligation of disrupted genetic material (1-3). Several mechanisms, such as non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ) and homologous recombination (HR), contribute to DSB repair and are employed variously during cell cycle depending on whether a specific DSB harbors either large, small, or no stretches (NHEJ, MMEJ, and HR, respectively) of complementary DNA sequences on the two fragments of broken DNA (4). In particular, the lethality of excess DSBs has been exploited for the therapeutic treatment of hereditary breast and ovarian cancers harboring BRCA1/2 mutations, which leads to defective HR and increased DSBs (5). These cancers exhibit synthetic lethality when treated with small molecule inhibitors of the PARP1 DNA repair enzyme, whose inhibition prevents a second method of DNA repair and leads to gross collapse of cellular DNA maintenance (6-8).

Recently, long noncoding RNAs (lncRNAs) have emerged as new layer of cell biology (9), contributing to diverse biological processes. In cancer, aberrant expression of lncRNAs is associated with cancer progression (9, 10), and overexpression of oncogenic lncRNAs can promote tumor cell proliferation and metastasis through transcriptional regulation of target genes (11-13). Recent studies have also identified lncRNAs induced by genotoxic stress as well as involved in the repair of DNA damage (14, 15); however, the role of lncRNAs in the regulation of DSB repair remains unclear.
Here, we report the characterization of PCAT-1 as a prostate cancer lncRNA implicated in the regulation of DSB repair. We find that PCAT-1 represses the BRCA2 tumor suppressor gene, leading to downstream impairment of HR. Importantly, PCAT-1 expressing cells exhibit a BRCA-like phenotype, resulting in cell sensitization to PARP1 inhibitors. In human prostate cancer tissues, high PCAT-1 expression predicts for low BRCA2 expression, supporting our observations in model systems. To our knowledge, this report is the first to demonstrate a role for lncRNAs in the regulation of DSBs in prostate cancer and suggests a new mechanistic basis for impaired HR in this disease.

**MATERIALS AND METHODS**

For full details on methodology, please refer to the Supplementary Information for a complete Materials and Methods section.

**Patient samples**

For the University of Michigan patient samples, prostate tissues were obtained from the radical prostatectomy series and Rapid Autopsy Program at the University of Michigan tissue core. These programs are part of the University of Michigan Prostate Cancer Specialized Program Of Research Excellence (S.P.O.R.E.). All tissue samples were collected with informed consent under an Institutional Review Board (IRB) approved protocol at the University of Michigan. (SPORE in Prostate Cancer (Tissue/Serum/Urine) Bank Institutional Review Board # 1994-0481). For the Weill Cornell Medical College patient samples, prostate tissues were collected as part of an IRB approved protocol at Weill Cornell Medical College.
Cell lines

All cell lines were obtained from the American Type Culture Collection (Manassas, VA). Cell lines were maintained using standard media and conditions. Du145-derived cell lines were maintained in DMEM supplemented with 10% FBS (Invitrogen) and 1% penicillin-streptomycin (Invitrogen) in a 5% CO₂ cell culture incubator. RWPE-derived cell lines were maintained in KSF (Invitrogen) supplemented with Bovine Pituitary Extract, Epidermal Growth Factor and 1% penicillin-streptomycin in a 5% CO₂ cell culture incubator. LNCAP-derived and PC3-derived were maintained in RPMI 1640 (Invitrogen) supplemented with 10% FBS and 1% penicillin-streptomycin in a 5% CO₂ cell culture incubator.

PC3 cells containing the GFP HR assay construct were generated as described previously (16, 17).

PCAT-1 or control-expressing cell lines were generated by cloning PCAT-1 or control LacZ into the pLenti6 vector (Invitrogen). After confirmation of the insert sequence, lentiviruses were generated at the University of Michigan Vector Core and transfected into RWPE or Du145 cells. Stably-transfected cells were selected using blasticidin (Invitrogen).

For LNCAP cells with stable knockdown of PCAT-1, cells were seeded at 50-60% confluency, incubated overnight, and transfected with PCAT-1 or non-targeting shRNA
lentiviral constructs for 48 hours. GFP+ cells were drug-selected using 1 ug/mL puromycin. PCAT-1 shRNAs were customed generated by Systems Biosciences using the following sequences: shRNA 1 GCAGAAACACCAAUGGAUAUU; shRNA 2 AUACAUAAAGACCAUGGAAAU.

To ensure cell identity, all cell lines were used for fewer than 6 months after resuscitation and confirmed by genotyping after resuscitation. DNA samples were diluted to 0.10ng/ul and nine genotyping loci (D3S1358, D5S818, D7S820, D8S1179, D13S317, D18S51, D21S11, FGA, vWA and the Amelogenin locus) were analyzed by the University of Michigan DNA Sequencing Core using the Profiler Plus PCR Amplification Kit (Applied Biosystems, Foster City, CA).

**Cell line assays**

LNCaP, Du145, PC3, and RWPE cell lines were obtained from the American Type Culture Collection (ATCC) and maintained in standard conditions. Stable overexpression and knockdown cell lines were generated with lentiviral constructs with blasticidin or puromycin selection as appropriate. RNA isolation and cDNA synthesis were performed according to standard protocols. Quantitative PCR was performed with Power SYBR Green Mastermix on an Applied Biosystems 7900HT Real-Time PCR system. Chemosensitivity assays were performed on 5000 cells plated per well in 96 well plates and treated with a single dose of Olaparib or ABT-888 as indicated for 72 hours. WST assays (Roche) were performed according to the manufacturer’s instructions. Immunofluorescence experiments were performed with 1 x 10^5 cells in 12-well plates.
according to standard protocols; RAD51 and γ-H2AX staining was performed 6 hours or 24 hours post-treatment, respectively.

**Luciferase Assays**

The indicated cell lines were transfected with full length *BRCA2* luciferase constructs as well as pRL-TK vector as internal control for luciferase activity. Following 2 days of incubation, the cells were lysed and luciferase assays conducted using the dual luciferase assay system (Promega, Madison, WI, USA). Each experiment was performed in quadruplicate.

**Immunoblot Analysis**

Cells were lysed in RIPA lysis buffer (Sigma, St. Louis, MO) and briefly sonicated for homogenization. Aliquots of each protein extract were boiled in sample buffer, size fractionated by SDS-PAGE at 4C, and transferred onto Polyvinylidene Difluoride membrane (GE Healthcare, Piscataway, NJ). The membrane was then incubated at room temperature for 1-2 hours in blocking buffer [Tris-buffered saline, 0.1% Tween (TBS-T), 5% nonfat dry milk] and incubated at 4C with the appropriate antibody. Following incubation, the blot was washed 4 times with TBS-T and incubated with horseradish peroxidase-conjugated secondary antibody. The blot was then washed 4 times with TBS-T and twice with TBS, and the signals visualized by enhanced chemiluminescence system as described by the manufacturer (GE Healthcare).
The following antibodies were used for immunoblot analysis: BRCA2 (EMD OP95), BRCA1 (Cell Signaling #9025S), XRCC1 (Abcam ab1838), XRCC3 (Abcam ab97390), XRCC4 (GeneTex GTX83406), Ku70 (BD Biosciences #611892), Ku80 (Cell Signaling #2180S), γ-H2AX (Cell Signaling #9718) and B-actin (Sigma A5441).

For immunoblot densitometry, the densitometric scan of the immunoblots was performed using ImageJ. Three replicate experiments were quantified for the final analysis.

**Xenograft assays**

Xenograft experiments were performed according to University of Michigan-approved protocols and conform to their relevant regulatory standards. Five week-old male SCID mice (CB.17. SCID), were purchased from Charles River, Inc. (Charles River Laboratory, Wilmington, MA). $1 \times 10^6$ Du145-control or Du145-PCAT-1 stable cells were resuspended in 100μl of saline with 50% Matrigel (BD Biosciences, Becton Drive, NJ) and were implanted subcutaneously into the left and right flank regions of the mice. Mice were anesthetized using a cocktail of xylazine (80-120 mg/kg, IP) and ketamine (10mg/kg, IP) for chemical restraint before tumor implantation. All tumors were staged for two weeks before starting the drug treatment. At the beginning of the third week, mice with tumors (10 tumors per treatment group, average size 150-200 mm3) were treated with Olaparib (100mg/kg, IP twice daily five times per week) or an equal volume of DMSO control. Growth in tumor volume was recorded weekly by using digital calipers.
I-SceI Homologous Recombination Assay

We followed previously described protocols (16). Briefly, PC-3 cells with a single copy of DR-GFP were transfected with empty vector control or PCAT-1. PCAT-1 transfected cells were infected with adenovirus-encoded I-SceI (adeno-I-SceI) at an MOI of 1000. Cells were harvested 3 days after infection and subjected to flow cytometry analysis for the GFP-positive cell population.

Statistical analyses for experimental studies

All data are presented as means ± standard deviation or S.E.M, as indicated. All experimental assays were performed in duplicate or triplicate. Statistical analyses shown in figures represent Fisher’s exact tests or Student’s t-tests, as indicated.

RESULTS

PCAT-1 regulates BRCA2 levels and homologous recombination

We previously reported the systematic nomination of lncRNAs associated with prostate cancer, termed Prostate Cancer Associated Transcripts (PCATs) (10). Among these, we noted that PCAT-1 expression was a prostate cancer outlier associated with low levels of BRCA2. We therefore hypothesized that PCAT-1 mediated the repression of BRCA2, and thus PCAT-1 may be implicated in the dysregulation of HR upon genotoxic stress. To pursue this hypothesis, we generated a panel of three in vitro cell culture model systems: PCAT-1 overexpression in Du145 prostate cancer cells (which lack endogenous expression of this lncRNA), PCAT-1 overexpression in RWPE benign prostate cells (which lack endogenous expression of this lncRNA), and stable knockdown
of \textit{PCAT-1} in LNCaP prostate cancer cells (which harbor high endogenous levels of \textit{PCAT-1} expression) (\textbf{Fig. 1A, left}).

Western blot analysis of these three isogenic models uniformly revealed strong downregulation of BRCA2 protein levels in RWPE and Du145 prostate cells and upregulation of BRCA2 in LNCaP sh-\textit{PCAT-1} cells (\textbf{Fig. 1A, right}). To ensure that these observations were not restricted to cell line-based studies, we further confirmed an inverse relationship between \textit{PCAT-1} and \textit{BRCA2} in two independent cohorts of human prostate cancer samples. Using 58 prostate cancer tissues and 20 prostate cancer xenografts derived from human specimens, we found that increasing \textit{PCAT-1} expression correlated with decreased \textit{BRCA2} expression (\textbf{Fig. 1B} and \textit{Supplementary Fig. S1A}). Together, these data suggest that \textit{PCAT-1} expression antagonizes \textit{BRCA2} expression.

Importantly, \textit{BRCA2} inactivation impairs HR of DSBs and serves as a predictive biomarker for response to treatment with inhibitors of the \textit{PARP1} DNA repair enzyme through synthetic lethality that results from joint inactivation of two DNA repair pathways (HR via \textit{BRCA2} inactivation, and base excision repair via \textit{PARP1} inhibition). Accordingly, treatment of our isogenic cell lines with either a PARP1 inhibitor (Olaparib or ABT-888) or radiation, resulted in modulation of RAD51 foci formation, which is a component of the HR pathway and a marker for engagement of the HR machinery (18). Specifically, \textit{PCAT-1} overexpression decreased RAD51 foci formation post-therapy and \textit{PCAT-1} knockdown increased RAD51 foci formation post-therapy in prostate (\textbf{Fig. 1C} and \textit{Supplementary Fig. S1B-D}). We further used a well-characterized HR assay, in which cells employ HR to recombine an I-Scel-cut plasmid to produce GFP signaling (16), to evaluate the function of \textit{PCAT-1} on HR directly. We found that transient
overexpression of \textit{PCAT-1} in PC3 prostate cancer cells resulted in a significant inhibition of GFP signaling following I-SceI-induced HR in addition to decreased RAD51 foci (Fig. 1D and Supplementary Fig. S2A-D). Of note, \textit{PCAT-1} expression does not show substantial change following induction of DNA damage via radiation (Supplementary Fig. S2E).

\textit{PCAT-1 expression impairs DNA damage repair}

Because \textit{PCAT-1} impairs HR, genotoxic stress of \textit{PCAT-1}-expressing cells should lead to an accumulation of DSBs, which can be visualized using gamma-H2AX (\(\gamma\text{H2AX}\)) foci, a marker of double-stranded DNA breaks that have not been repaired (4). To test this, we treated our isogenic Du145 and LNCaP cell line models with Olaparib, ABT-888, or radiation. As predicted, \textit{PCAT-1} overexpression in Du145 led to an increase in \(\gamma\text{H2AX}\) foci under stress conditions (Fig. 2A, B), indicating that \textit{PCAT-1} impairs DSB repair in these cells. Similarly, LNCaP cells with \textit{PCAT-1} knockdown displayed decreased levels of \(\gamma\text{H2AX}\) foci (Fig. 2A, B). Immunoblot analysis of \(\gamma\text{H2AX}\) protein abundance in these cells following genotoxic stress confirmed a downregulation of \(\gamma\text{H2AX}\) with knockdown of \textit{PCAT-1} and upregulation of \(\gamma\text{H2AX}\) with overexpression of \textit{PCAT-1} (Supplementary Fig. S3).

Finally, we also evaluated the ability for our isogenic cell lines to sustain growth in clonogenic survival assays, a gold-standard assay for cell viability following genotoxic stress, after treatment of cells with PARP1 inhibition or radiation. We found that \textit{PCAT-1} expression led to decreased cell survival in Du145 and RWPE cells, whereas \textit{PCAT-1} knockdown increased LNCaP cell survival, in these assays (Supplementary Fig. S4).
To exclude a regulatory relationship between PCAT-1 and other major actors in DNA damage, we performed analysis of XRCC1 (base excision repair pathway), XRCC3 (HR), XRCC4 (NHEJ), Ku70 (NHEJ), Ku80 (NHEJ), and BRCA1 (multiple pathways) in our in vitro models, which showed no change in protein abundance upon modulation of PCAT-1 (Supplementary Fig. S5A). Together, these data indicate that PCAT-1 expression may impart cell sensitivity to genotoxic stress by decreasing the HR response through downregulation of BRCA2.

**PCAT-1 expression leads to increased cell death following genotoxic stress**

Because PCAT-1 expressing cells exhibit reduced HR efficiency when challenged, we investigated whether PARP1 inhibition selectively killed PCAT-1-expressing cells. Following treatment with two PARP1 inhibitors (Olaparib or ABT-888), we observed that knockdown of PCAT-1 in LNCaP cells prevented cell death, whereas overexpression of PCAT-1 in Du145 and RWPE prostate cells increased cell death in response to PARP inhibition (Fig. 3A, left and Supplementary Fig. S5B-D). This change in cell sensitivity to PARP1 inhibitors was striking, with a five-fold change in the IC50 for LNCaP and Du145 cells (Fig. 3A, right and Supplementary Fig. S6). Similar results were observed in RWPE cells overexpressing PCAT-1 (Supplementary Fig. S7).

To ensure that these effects were dependent on BRCA2, we performed a rescue experiments by performing knockdown of BRCA2 in LNCaP shPCAT-1 cells (which have increased levels of BRCA2). These experiments demonstrated a corresponding increase in the sensitivity of these cells to PARP1 inhibition in a dose-dependent manner.
according to the efficiency of the \textit{BRCA2} knockdown (Fig. 3B). We further observed reduced RAD51 foci post-treatment following \textit{BRCA2} knockdown in LNCaP sh\textit{PCAT-1} cells as well (Supplementary Fig. S8). To exclude a role for altered cell cycle distributions in these phenotypes, we performed flow cytometry, which demonstrated no change in cell cycle in our model systems (Supplementary Fig. S9).

\textit{PCAT-1} expression leads to decreased in vivo tumor growth following PARP inhibition

To evaluate the contribution of \textit{PCAT-1} to PARP inhibitor response \textit{in vivo}, we generated xenografts of Du145 cells expressing either empty vector control or \textit{PCAT-1}. We observed that Du145-\textit{PCAT-1} cells grew significantly more rapidly in severe combined immunodeficient (SCID) mice, consistent with our previous findings that \textit{PCAT-1} accelerates prostate cell proliferation \textit{in vitro} (Fig. 3C) (10). Moreover, Du145-\textit{PCAT-1} xenografts showed marked susceptibility and tumor regression following intraperitoneal (IP) administration of Olaparib, whereas Du145-control cells showed only a subtle change in growth while the drug was administered, indicating that the background effect of Olaparib therapy—possibly due to its effects on other members of the PARP family (19)—is small (Fig. 3C). Mice in all groups of treatment maintained their body weights and showed no evidence of weight loss (Supplementary Fig. S10A).

Importantly, Du145 xenografts retained both \textit{PCAT-1} expression and \textit{BRCA2} repression (Fig. 3D). To investigate \textit{PCAT-1} signaling under control-treated (DMSO) and Olaparib-treated conditions, we also observed \textit{in vivo} upregulation of \textit{PCAT-1}-induced target genes (\textit{TOP2A}, \textit{E2F8}, \textit{BIRC5}, and \textit{KIF15}) (Supplementary Fig. S10B), defined by previous microarray profiling of LNCaP cells with \textit{PCAT-1} siRNAs and
confirmed in RWPE-PCAT-1 overexpressing cells (Supplementary Fig. S10C) (10). These data suggest that PCAT-1 is mechanistically linked to increased prostate cell sensitivity to PARP1 inhibitors via its repression of BRCA2 both in vitro and in vivo.

**PCAT-1 does not operate via traditional lncRNA-mediated mechanisms**

While many lncRNAs are noted to regulate gene transcription through epigenetic mechanisms (11, 13, 20), we did not observe evidence for this possibility with PCAT-1. While PCAT-1 regulated BRCA2 mRNA in vitro (Supplementary Fig. S11A), treatment of RWPE-LacZ and RWPE-PCAT-1 cells with the DNA methylation inhibitor 5-azacytidine (5-aza), the histone deacetylase inhibitor TSA, or both did not reveal enhanced epigenetic regulation of BRCA2 mRNA in PCAT-1-expressing cells (Supplementary Fig. S11B), although there was a baseline regulation of BRCA2 in both cell lines when 5-aza and TSA were combined. Furthermore, bisulfite sequencing of the BRCA2 promoter in our isogenic LNCaP and RWPE model systems demonstrated minimal CpG island methylation in all cell lines (Supplementary Fig. S11C). These results suggest that epigenetic repression of BRCA2 is not the primary mechanism of PCAT-1. Moreover, lncRNAs containing Alu elements in their transcript sequence may utilize these repetitive sequences to regulate target gene mRNAs via STAU1-dependent degradation (21). Although PCAT-1 harbors an Alu element from bps 1103 – 1402, knockdown of STAU1 in LNCaP or VCaP cells, which endogenously harbor PCAT-1, did not alter BRCA2 levels (Supplementary Fig. S11D).

**PCAT-1 regulates BRCA2 post-transcriptionally**
To determine whether PCAT-1 may function in a manner more analogous to microRNAs, which regulate mRNA levels post-transcriptionally (22), we generated a luciferase construct of the BRCA2 3’UTR, which is 902 bps in length (Fig. 4A). Surprisingly, we found that RWPE-PCAT-1 cells, but not control RWPE-LacZ cells, were able to directly repress the activity of the wild-type BRCA2 3’UTR construct (Fig. 4A). Supporting these data, we found that PCAT-1 was localized to the cell cytoplasm (Supplementary Fig. S12A), and overexpression of PCAT-1 in Du145 cells significantly reduced the stability of endogenous BRCA2 mRNA, consistent with a post-transcriptional mechanism (Supplementary Fig. S12B, C).

To map a region of PCAT-1 required for repression of the BRCA2 3’UTR, we additionally generated a series of PCAT-1 deletion constructs and overexpressed these in RWPE cells (Fig. 4B and Supplementary Fig. S13A). We generated these constructs to establish whether the 3’ end of PCAT-1, which contains portions of ancestral transposase and Alu repeat elements (Fig. 4B) (10), or the 5’ end of PCAT-1, which consists of non-repetitive DNA sequences, was required for BRCA2 repression. We observed that the 5’ end of PCAT-1 was sufficient to downregulate the BRCA2 3’UTR luciferase signal as well as endogenous BRCA2 transcript levels (Fig. 4B, C), and for this regulation, the first 250 bps of the PCAT-1 gene were required. By contrast, the 3’ end of PCAT-1 was expendable. Importantly, the 5’ end of PCAT-1 was similarly sufficient to sensitize RWPE cells to Olaparib treatment in vitro (Fig. 4D). To rule out the possibility that RNA instability was responsible for the inactivity of the PCAT-1 constructs, we performed RNA stability assays, which demonstrated equivalent rates of RNA decay between full-length PCAT-1 and the inactive PCAT-1 deletion constructs in RWPE cells.
Together, these results indicate that PCAT-1 overexpression is able to directly repress the activity of the BRCA2 3’UTR, and that this repression required the 5’ end of PCAT-1.

**DISCUSSION**

To our knowledge, this is the first report of a lncRNA being involved in the DSB repair process in prostate cancer (Supplementary Fig. S14). These data are supported by a striking inverse correlation between PCAT-1 and BRCA2 expression in human prostate cancer samples. Our results expand the potential roles for lncRNAs in cancer biology and contrast strikingly with previous reports that lncRNAs operate epigenetically through chromatin modifying complexes (23, 24). Indeed, epigenetic regulation likely represents only a one of numerous mechanisms for lncRNA function (12, 21, 25, 26). Supporting this notion, we do not observe compelling evidence that PCAT-1 functions in an epigenetic manner, but rather it may exhibit post-transcriptional regulation of its target genes.

Importantly, PCAT-1 is also predominantly cytoplasmic, and thus our work describes the first cytoplasmic prostate lncRNA to be associated with therapeutic response. Cytoplasmic lncRNAs are also less well explored than their nuclear counterparts, and our work sheds light onto the complex mechanistic regulation of cellular processes via cytoplasmic lncRNAs. However, PCAT-1 does exhibit a smaller degree of nuclear expression (see Supplementary Figure 12A), which may account for our previous observation that PCAT-1 may associate with the nuclear Polycomb Repressive Complex 2 (PRC2). As such, while our data directly support a role for
PCAT-1 in the post-transcriptional regulation of BRCA2, we cannot fully exclude the possibility of additional regulation of BRCA2 at the transcriptional level at this time.

In addition, while the mechanism underlying PCAT-1 function remains incompletely understood, we were intrigued that the 5’ portion of the PCAT-1 RNA, which is comprised of fully unique sequences, was critical for its regulation of BRCA2 mRNA whereas the embedded Alu element was not. While we did not identify a specific microRNA with high-confidence 7-mer complementary basepair matching to both this region of PCAT-1 and BRCA2 (data not shown), we speculate that alternative mechanisms of miRNA-like mismatch base pairing may contribute to PCAT-1-mediated regulation in a manner similar to the recently described networks of competing endogenous RNAs (ceRNAs) (27).

Together, our data suggest that lncRNAs may have a more widespread role in mammalian genome maintenance and DNA repair than previously appreciated. In support of this, a role for small RNAs in human DNA damage repair in human cells has been recently reported and shown to be dependent upon the microRNA biogenesis machinery (28). Of note, Adamson et al. nominated the RNA-binding protein RBMX as a novel component of the HR pathway (16), suggesting that RNA-protein interactions may be integral to this process.

This work sheds insight onto potential mechanisms of impaired DSB repair in cancers lacking an inactivating mutation in canonical DSB repair proteins. Thus, our studies have uncovered a novel mechanism of “BRCA-ness”—the clinical observation that many cancers lacking BRCA1/BRCA2 mutations exhibit the clinical features of impaired DSB repair (2, 29, 30). We hypothesize that other cancers with a BRCA-like
phenotype may harbor IncRNAs involved in the regulation and execution of proper HR and other forms of DSB repair. Finally, future clinical trials examining the efficacy of PARP1 inhibitors in prostate cancer will provide critical information as to whether *PCAT-1* may serve as a predictive biomarker for patient response to PARP1 inhibitor therapy.
ACKNOWLEDGEMENTS

We thank Mats Ljungman, Saravana M. Dhanasekaran, Chad Brenner, Yi-Mi Wu, Daniel Robinson, Sameek Roychowdhury, and Dan Hamstra for helpful discussions. We thank Benjamin Chandler for technical assistance. This work was supported in part by the Prostate Cancer Foundation (F.Y.F. and A.M.C.), NIH Prostate Specialized Program of Research Excellence grant P50CA69568, Department of Defense grants PC094231 (F.Y.F.) and PC100171 (A.M.C.), the Early Detection Research Network grant UO1 CA111275 (A.M.C.), the Prostate Cancer Foundation-Movember Challenge Award (to K.E.K., F.Y.F., and M.A.R.), the US National Institutes of Health R01CA132874-01A1 (A.M.C.) and R01CA152057 (M.A.R., F.D.), and the National Center for Functional Genomics support by the Department of Defense (to A.M.C.). A.M.C. is also supported by the Doris Duke Charitable Foundation Clinical Scientist Award and the Howard Hughes Medical Institute. A.M.C. is an American Cancer Society Research Professor and a Taubman Scholar of the University of Michigan. J.R.P., M.K.I, and Q.C. were supported by the Department of Defense Fellowship grants PC094290 (to J.R.P), BC100238 (to M.K.I) and PC094725 (to Q.C.). J.R.P. was supported by a Prostate Cancer Foundation Young Investigator award. J.R.P., A.S., and M.K.I. are Fellows of the University of Michigan Medical Scientist Training Program.

Author Contributions

Conception and design: J.R. Prensner, W. Chen, A.M. Chinnaiyan, F.Y. Feng

Development of methodology: W. Chen, J.R. Prensner, S. Han, T. Ma, M.K. Iyer, F.Y. Feng


Writing, review and/or revision of the manuscript: J.R. Prensner, W. Chen, M.K. Iyer, A.M. Chinnaiyan, F.Y. Feng

Administrative, technical, or material support: T.S. Lawrence, K.E. Knudsen, F.Y. Feng

Study supervision: J.R. Prensner, A.M. Chinnaiyan, F.Y. Feng

Correspondence

All correspondence and requests for materials should be addressed to ffeng@med.umich.edu and arul@med.umich.edu

REFERENCES


22


FIGURE LEGENDS

Figure 1. *PCAT-1* expression leads to defective homologous recombination in prostate cells. **A,** Left, Expression level of *PCAT-1* by qPCR in three isogenic cell lines with overexpression (Du145, RWPE) or knockdown (LNCaP) of *PCAT-1*. Error bars indicate S.E.M. **Right,** Western blot analysis of BRCA2 in three isogenic cell lines with overexpression (Du145, RWPE) or knockdown (LNCaP) of *PCAT-1*. **B,** Expression of *PCAT-1* and *BRCA2* in a cohort of prostate cancer patients. Expression is shown as z-scores and stratified by increasing *PCAT-1* expression. P values are determined by a Mann-Whitney U test. **C,** Left, Quantification of RAD51 foci in isogenic Du145 and LNCaP cell lines following 2 Gy of radiation or treatment with 25μM Olaparib. For LNCaP cell line models, cells with > 5 foci per cell were quantified. For Du145 cell line models, cells with > 10 foci per cell were quantified. Error bars represent standard deviation. An asterisk (*) indicates p < 0.05 by Student’s t-test. **Right,** Induction of RAD51 foci in Du145-*PCAT-1* cells following 2 Gy of ionizing radiation or treatment with 25μM Olaparib. **D,** I-SceI-mediated GFP HR assay in PC3-*PCAT-1* cells compared to matched control cells. Error bars represent S.E.M.

Figure 2. *PCAT-1* knockdown reduces γH2AX foci formation following genotoxic stress. **A,** LNCaP or Du145 cells with knockdown or overexpression for *PCAT-1* were subjected to 4 Gy of ionizing radiation, 25μM Olaparib, 100μM of ABT-888, or control DMSO. 24 hours post-treatment, cells were fixed and stained for γH2AX and counterstained for DAPI. **B,** Quantification of γH2AX foci in LNCaP and Du145 isogenic *PCAT-1* cells.
treated with radiation or PARP inhibitors. For LNCaP cell line models, cells with > 5 foci per cell were quantified. For Du145 cell line models, cells with > 10 foci per cell were quantified. Error bars represent the standard deviation. An asterisk (*) indicates p < 0.05 by Student’s t-test.

Figure 3. PCAT-1 expression results in prostate cell sensitivity to PARP inhibition in vitro and in vivo. A, Left, LNCaP cells with PCAT-1 knockdown exhibit enhanced cell survival 72 hrs post-treatment with Olaparib. Right, Du145 cells with PCAT-1 overexpression exhibit reduced cell survival 72 hrs post-treatment with Olaparib. Cell survival is determined via WST assays. B, BRCA2 knockdown in LNCaP shPCAT-1 cells rescues cell sensitivity to Olaparib. An inset Western blot showing efficiency of BRCA2 knockdown is included. C, Tumor growth curves for Du145-control and Du145-PCAT-1 xenografts following initiation of treatment with DMSO control or 25μM Olaparib. Tumor volumes are normalized to 100, and time = 0 represents the start of treatment administration. Treatment was initiated three weeks after xenograft engraftment. D, Expression level of PCAT-1 and BRCA2 protein in Du145-PCAT-1 xenografts. Error bars in this figure represent +/- S.E.M.

Figure 4. The 5′ terminus of PCAT-1 represses BRCA2 mRNA via the 3′UTR of BRCA2. A, Transfection of a BRCA2 3′UTR luciferase construct in RWPE-PCAT-1 cells. B, A schematic of PCAT-1 deletion constructs overexpressed in RWPE cells. PCAT-1 del (1-750 bps) was able to recapitulate repression of the BRCA2 3′UTR luciferase construct. C, Endogenous BRCA2 transcript levels in RWPE cells overexpressing PCAT-1 deletion
constructs. **D**, Treatment of RWPE cells overexpressing *PCAT-1* deletion constructs with 25uM Olaparib. Cell survival was measured 72 hrs post-treatment with WST. Error bars in this figure represent +/- S.E.M. An asterisk (*) indicates p < 0.05 by Student’s t-test.
A

PCAT1 expression (Log2 fold)

<table>
<thead>
<tr>
<th>LNCaP</th>
<th>Du145</th>
<th>RWPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>sh-NT</td>
<td>Control</td>
<td>PCAT1</td>
</tr>
<tr>
<td>sh-PCAT1 #1</td>
<td>sh-PCAT1 #2</td>
<td>Control</td>
</tr>
</tbody>
</table>

BRCA2,
B-actin

B

Standardized expression (z-score)

PCAT1 expression

<table>
<thead>
<tr>
<th>PCAT1 low (n = 14)</th>
<th>PCAT1 mid (n = 30)</th>
<th>PCAT1 high (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNCaP</td>
<td>Du145</td>
<td>RWPE</td>
</tr>
<tr>
<td>sh-NT</td>
<td>Control</td>
<td>PCAT1 pool</td>
</tr>
<tr>
<td>sh-PCAT1 #1</td>
<td>sh-PCAT1 #2</td>
<td>PCAT1 clone 2</td>
</tr>
</tbody>
</table>

PCAT1 expression BRCA2 expression

0 hrs 6 hrs

Percent of cells

<table>
<thead>
<tr>
<th>Du145 control</th>
<th>Du145 PCAT-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 hr</td>
<td>6 hr</td>
</tr>
<tr>
<td>2 Gy Radiation</td>
<td>25 uM Olaparib</td>
</tr>
</tbody>
</table>

25 uM Olaparib

DAPI
RAD51
Merge

D

Relative HR efficiency
(Normalized GFP signal intensity)

<table>
<thead>
<tr>
<th>I-Sce1</th>
<th>Control</th>
<th>PCAT-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

p < 0.05
**A**

BRCA2

CDS

3'UTR

0 227 1048 1138

**B**

Relative Luciferase Activity

PCAT1

PCAT1 del (500-1992)

PCAT1 del (1-750)

PCAT1 del (250-1500)

LacZ

PCAT1 pool

PCAT1 clone 2

PCAT1 del (500-1992)

PCAT1 del (1-750)

PCAT1 del (250-1500)

**C**

Relative BRCA2 expression

LacZ

PCAT1 pool

PCAT1 clone 2

PCAT1 del (500-1992)

PCAT1 del (1-750)

PCAT1 del (250-1500)

**D**

Fraction of cells surviving

LacZ

PCAT1 pool

PCAT1 clone 2

PCAT1 del (500-1992)

PCAT1 del (1-750)

PCAT1 del (250-1500)
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer


Cancer Res  Published OnlineFirst January 28, 2014.

Updated version
Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-3159

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/05/23/0008-5472.CAN-13-3159.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.